Liver Cancer Diagnostic Market Size, Share & Trends Report

Liver Cancer Diagnostic Market Size, Share & Trends Analysis Report By Screening Type (Biopsy, Endoscopy, Laboratory Tests, Imaging), By Region (North America, APAC, Europe), And Segment Forecasts, 2019 - 2025

  • Published Date: Jan, 2019
  • Base Year for Estimate: 2017
  • Report ID: GVR-3-68038-012-5
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 111

Report Overview

The global liver cancer diagnostic market size was valued at USD 8.25 billion in 2017 and is projected to expand at a healthy CAGR of 8.1% during the forecast period. Rising disease incidence, growing awareness, and increased usage of advanced cancer screening products are some of the key factors propelling the market growth. Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer in adults. Various risk factors have been associated with HCC, which include hepatitis, obesity, alcohol-induced cirrhosis, exposure to dietary aflatoxin, and diabetes. It can be prevented at an early stage by various screening procedures, such as lab tests, imaging, and endoscopy. This is also augmenting the market growth.

U.K. liver cancer diagnostic market

Environmental pollution and excessive alcohol and tobacco consumption are the major causes of liver cancer. According to the World Health Organization (WHO), alcohol consumption is the primary causal factor in 20% - 50% of liver cirrhosis cases. Since 1980, obesity has increased significantly with approximately 13% of the world’s population classified as obese by the WHO. Obesity increases the risk of non-alcoholic fatty liver disease. Growing prevalence of hepatitis B and C infections are also expected to fuel the demand for liver cancer diagnostic procedures.

Increased prevalence of cancer, adoption of new detection techniques, and availability of efficient cancer treatments are also driving the market. In addition, supportive government initiatives that help raise awareness regarding the disease and favorable reimbursement facilities under the Affordable Care Act are boosting the market growth. Accurate detection of the progression of cancer is essential for the selection of appropriate treatment regimens. At present, the available tests show false-positive results in some cases. Thus, confirmatory tests are required, which increases the monetary burden on patients.

Tests using specific biomarkers and tumor markers give comparatively more accurate results. This presents an opportunity for industry participants to develop tumor-specific biomarkers and improved diagnostic procedures for liver carcinoma. Unmet need for treatments providing complete remissions and long-lasting response exists in the HCC space, which presents a strong opportunity to develop breakthrough first-in-class diagnostic procedures and therapies.

Screening Type Insights

The screening type segment includes laboratory tests, imaging, endoscopy, biopsy, and others. Laboratory tests include testing of blood, urine, and other body fluids or tissue samples that help identify the presence of cancerous cells/tissue in the body. Laboratory tests for HCC diagnosis include Alpha-fetoprotein (AFP) blood test, liver function test, other blood tests for the detection of tumor markers and clotting factors, immunophenotyping, sputum cytology, urinalysis, and urine cytology. The aforementioned tests aid in detection of abnormalities in cell and tissue structure.

U.S. liver cancer diagnostic market

Imaging tests help take images of the internal organs to detect/confirm the presence of tumor. Available imaging tests for liver cancer diagnosis include Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI) scan, X-ray, ultrasound, and other radiographic tests. Furthermore, MRI-compatible pacemakers are now available, which allow scanning of patients with pacemakers. Patients with new compatible pacemakers are only eligible for MRI imaging tests for cancer diagnosis. Thus, the imaging segment is expected to witness a significant CAGR of 8.1% over the forecast period. Other diagnostic tests include biopsy, laparoscopy, and bone scans.

Regional Insights

North America led the global market in 2017 accounting for more than 35% market share. The region is expected to maintain the leading position throughout the forecast period supported by excellent healthcare coverage and technological advancements. The U.S. spearheads the market in North America region. Presence of a large base of target population, demand for care diagnostics, improved technology, and quick adoption of novel therapeutics and diagnostic approaches are the key factors responsible for the region’s large share.

Asia Pacific is expected to exhibit the highest growth due to increasing incidences of liver cancer and growing importance of lowering the cost of cancer treatments in developing countries, such as India and China. Growing medical tourism industry in these countries is also expected to boost the demand for diagnostic procedures for liver carcinoma. In addition, increased investments in research & development and favorable government policies for healthcare devices manufacturers are anticipated to drive the region’s growth further.

Key Companies & Market Share Insights

The global market is highly competitive. Some of the major companies in the industry include Illumina, Inc.; Qiagen; F. Hoffmann-La Roche Ltd.; Siemens Healthcare GmbH; and Thermo Fisher Scientific. These companies are focused on product portfolio expansion and mergers and acquisitions to maintain their market share.

Liver Cancer Diagnostics Market Report Scope

Report Attribute


Market size value in 2020

USD 10.6 billion

Revenue forecast in 2025

USD 15.4 billion

Growth Rate

CAGR of 8.1% from 2019 to 2025

Base year for estimation


Historical data

2014 - 2016

Forecast period

2019 - 2025

Quantitative units

Revenue in USD Million and CAGR from 2019 to 2025

Report coverage

Revenue forecast; company share; competitive landscape; growth factors and trends

Segments covered

Screening type, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K.; Japan; China; Brazil; Mexico; Saudi Arabia; South Africa

Key companies profiled

Illumina; Inc.; Qiagen; F. Hoffmann-La Roche Ltd.; Siemens Healthcare GmbH; Thermo Fisher Scientific.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global liver cancer diagnostic market report on the basis of screening type and region:

  • Screening Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Laboratory Tests

      • Biomarkers

        • Oncofetal and Glycoprotein Antigens

        • Enzymes and Isoenzymes

        • Growth Factors and Receptors

        • Molecular Markers

        • Pathological Biomarkers

      • Blood Tests

    • Imaging

    • Endoscopy

    • Biopsy

    • Others

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • The U.K.

      • Germany

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.